Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma

Immune checkpoint inhibitors (CPIs), including pembrolizumab, are becoming common oncological treatments. CPIs have been associated with a significant risk of developing immune-related adverse events (irAEs), such as nephritis and interstitial nephritis. However, the occurrence of glomerulonephritis...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Internal Medicine 2020/04/01, Vol.59(7), pp.977-981
Hauptverfasser:	Oki, Rikako, Hirakawa, Yosuke, Kimura, Hitomi, Honda, Kenjiro, Hinata, Munetoshi, Abe, Hiroyuki, Domoto, Yukako, Tanaka, Goh, Nagase, Takahide, Nangaku, Masaomi
Format:	Artikel
Sprache:	eng
Schlagworte:	acute tubulointerstitial nephritis Biopsy Case Report Glomerulonephritis Hematuria IgA nephropathy Immune checkpoint inhibitors immune checkpoint inhibitors (CPI) immune-related adverse events (irAEs) Immunoglobulin A Internal medicine Kidneys Lung carcinoma Monoclonal antibodies Nephritis Non-small cell lung carcinoma onconephrology Pembrolizumab Proteinuria Small cell lung carcinoma Urinalysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!